As Tanegashima et al. [37] discovered, the individual or simultaneous expression of PD-L2 with PD-L1 in cancer cells inhibited antitumor immunity, which was related to the resistance to anti-PD-L1 treatment that was found in preclinical animal models. This evidence concerns the gene PDCD1LG2 and cancer.